Virtus ETF Advisers’s Adaptimmune Therapeutics ADAP Stock Holding History

Virtus ETF Advisers’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-44,300	Closed	-$91K	–	435
2022 Q1	$91K	Sell	44,300 -2,631	-6%	-$7.1K	0.04%	318
2021 Q4	$176K	Sell	46,931 -419	-0.9%	-$1.91K	0.07%	258
2021 Q3	$245K	Sell	47,350 -2,469	-5%	-$11.1K	0.11%	222
2021 Q2	$212K	Sell	49,819 -23,418	-32%	-$114K	0.09%	303
2021 Q1	$389K	Buy	73,237 +1,283	+2%	+$7.34K	0.16%	187
2020 Q4	$388K	Buy	71,954 +40,945	+132%	+$222K	0.16%	157
2020 Q3	$247K	Sell	31,009 -4,232	-12%	-$37K	0.13%	264
2020 Q2	$353K	Buy	+35,241	New	+$221K	0.17%	261
2019 Q2	–	Sell	-50,655	Closed	-$218K	–	436
2019 Q1	$218K	Sell	50,655 -7,568	-13%	-$35.2K	0.46%	85
2018 Q4	$335K	Buy	58,223 +20,620	+55%	+$152K	0.06%	91
2018 Q3	$510K	Sell	37,603 -27,618	-42%	-$290K	0.05%	120
2018 Q2	$774K	Buy	+65,221	New	+$813K	0.68%	48
2016 Q4	–	Sell	-26,974	Closed	-$190K	–	177
2016 Q3	$190K	Hold	26,974	–	–	0.09%	141
2016 Q2	$220K	Sell	26,974 -1,208	-4%	-$11.4K	0.16%	126
2016 Q1	$229K	Buy	+28,182	New	+$230K	0.32%	69

Other funds holding ADAP

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Virtus ETF Advisers's ADAP Position: Q2 2022 in Review

Virtus ETF Advisers sold out of Adaptimmune Therapeutics (ADAP) in Q2 2022, closing a stake of 44,300 shares — an estimated $91K sold.

Virtus ETF Advisers first reported a position in ADAP in Q1 2016 and held it in 15 quarters. The position peaked at $774K in Q2 2018. 77 funds tracked by Wall St. Rank hold ADAP as of Q2 2022.

Virtus ETF Advisers reported no remaining Adaptimmune Therapeutics position as of Q2 2022 after selling out during the quarter.
Virtus ETF Advisers sold 44,300 Adaptimmune Therapeutics shares in Q2 2022, an estimated $91K.
Virtus ETF Advisers first reported a position in Adaptimmune Therapeutics in Q1 2016 and held it in 15 quarters.
Virtus ETF Advisers's Adaptimmune Therapeutics position peaked at $774K in Q2 2018.
77 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q2 2022.

Based on Virtus ETF Advisers's 13F filing for Q2 2022, filed 12 Aug 2022.